Onco-Innovations Limited (NEO:ONCO)

Canada flag Canada · Delayed Price · Currency is CAD
1.560
-0.040 (-2.50%)
Dec 4, 2025, 9:30 AM EST
160.00%
Market Cap 91.01M
Revenue (ttm) 84.79K
Net Income (ttm) -10.83M
Shares Out 56.18M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,050
Average Volume 37,941
Open 1.600
Previous Close 1.600
Day's Range 1.560 - 1.600
52-Week Range 0.560 - 2.800
Beta n/a
RSI 42.33
Earnings Date Dec 12, 2025

About Onco-Innovations

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company’s lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3′-Phosphatase (PNKP) in a nanoparticle formulation based on the drug delivery technology. Onco-Innovations Limited is headquartered in Calgary, Canada. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Thomas O’Shaughnessy
Employees 1
Stock Exchange Cboe Canada
Ticker Symbol ONCO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.